What antidepressant is appropriate as first-line therapy for a 58-year-old man with mild-to-moderate depression, a family history of glaucoma, and a desire to avoid sedation and visual disturbances?

Recommended Antidepressant for a 58-Year-Old Male with Mild-to-Moderate Depression and Family History of Glaucoma

Sertraline or citalopram are the optimal first-line choices for this patient, starting at 25–50 mg daily for sertraline or 10 mg daily for citalopram, as these SSRIs have the best evidence for efficacy and tolerability in this age group while avoiding the anticholinergic and sedating effects that could worsen glaucoma risk or cause visual disturbances. 1

Why SSRIs Are Preferred Over Other Antidepressants

Bupropion Should Be Avoided Despite Its Advantages

While bupropion is typically an excellent first-line agent for patients concerned about sedation and cognitive symptoms 1, 2, it carries a nearly 2-fold increased risk of angle-closure glaucoma in patients under 50 years (adjusted rate ratio 1.98) and should be used with extreme caution in patients with any glaucoma risk factors, including family history 3. Although your patient is 58 years old, the elevated risk in younger patients suggests a mechanism that warrants avoidance when safer alternatives exist 3, 4.

Tricyclic Antidepressants Are Contraindicated

TCAs like amitriptyline produce severe anticholinergic effects that can precipitate angle-closure glaucoma and cause marked blurred vision 1, 5. They should never be used as first-line agents in this population 1, 2.

Other Antidepressants to Avoid

• Paroxetine has the highest anticholinergic burden among SSRIs and should not be used in older adults 1, 2
• Fluoxetine carries greater risk of agitation and overstimulation in this age group 1
• Venlafaxine (SNRI) is a reasonable alternative but requires blood pressure monitoring and has no clear advantage over SSRIs for this patient's presentation 1

Specific Dosing and Monitoring Protocol

Starting Doses

• Sertraline: Begin at 25–50 mg once daily in the morning; target dose 50–100 mg daily 1
• Citalopram: Begin at 10 mg once daily in the morning; maximum dose 20 mg daily (never exceed this in patients >60 years due to QT prolongation risk) 1

Baseline Assessments

• Sodium level (to detect hyponatremia risk, which occurs in 0.5–12% of elderly patients on SSRIs) 1
• ECG if cardiac risk factors are present 1
• Blood pressure (supine and standing) to assess orthostatic hypotension risk 1

Follow-Up Schedule

• Week 4: Assess treatment response using standardized scales (PHQ-9 or similar) 1, 2
• Week 8: Reassess efficacy; if inadequate response, increase dose or consider augmentation with bupropion SR 150 mg daily (though this adds glaucoma risk) 1
• Month 3: Confirm sustained response 1

Treatment Duration

• First episode: Continue for 4–12 months after achieving remission 1, 2
• Recurrent depression (≥3 episodes): Consider indefinite maintenance at the lowest effective dose, as recurrence risk approaches 90% 1

Critical Safety Warnings Specific to This Patient

Glaucoma Monitoring

• Family history of glaucoma does not contraindicate SSRIs, as the evidence for SSRIs increasing angle-closure risk remains unclear and controversial 5, 4
• Refer to ophthalmology for baseline screening if the patient has never been evaluated, given his family history 5
• Instruct the patient to report immediately any acute eye pain, halos around lights, or sudden vision changes 5

Bleeding Risk

• If the patient takes NSAIDs or antiplatelet agents (aspirin, clopidogrel), the combination with SSRIs increases GI bleeding risk 15-fold (adjusted OR 15.6) 1
• Add a proton pump inhibitor for gastroprotection if concurrent NSAID/antiplatelet use is necessary 1

Hyponatremia

• Check sodium level within the first month of treatment, as elderly patients are at substantially greater risk due to age-related changes in renal function 1
• Do not discontinue monitoring after initial titration, as hyponatremia can occur at any time 1

Why Not Cognitive Behavioral Therapy Alone?

While CBT demonstrates equivalent efficacy to antidepressants for moderate depression 6, 1, the question specifically requests an antidepressant recommendation. For patients who prefer non-pharmacologic treatment or have concerns about polypharmacy, CBT is an equally valid first-line option and may produce lower relapse rates after remission 1, 2.

Common Pitfalls to Avoid

• Do not use standard adult starting doses—always reduce by approximately 50% in patients ≥60 years 1
• Do not prescribe paroxetine or fluoxetine as first-line agents in this age group 1, 2
• Do not combine SSRIs with NSAIDs without gastroprotection given the 15-fold increased bleeding risk 1
• Do not assume bupropion is safe simply because it lacks anticholinergic effects; the glaucoma risk data are concerning in patients with family history 3, 4